Thromb Haemost 1995; 74(05): 1231-1234
DOI: 10.1055/s-0038-1649917
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Increased Plasma Thrombin-Antithrombin III Complex Levels in Non-Insulin Dependent Diabetic Patients with Albuminuria Are Reduced by Ethyl Icosapentatenoate

Hiroyuki Shimizu
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Ken-Ichi Ohtani
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Yoshito Tanaka
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Akira Fukatsu
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Yutaka Uehara
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Noriyuki Sato
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Masatomo Mori
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
› Author Affiliations
Further Information

Publication History

Received 16 January 1995

Accepted after resubmission 20 July 1995

Publication Date:
10 July 2018 (online)

Preview

Summary

Hypercoagulability may increase the risk of cardiovascular disease (CVD) in diabetic patients with albuminuria. Plasma thrombin-antithrombin III complex (TAT) levels, representing a functional state of clotting system, were studied in one hundred and fifteen non-insulin- dependent diabetic (NIDDM) patients. The patients were divided into three groups according to the urine albumin index (UAI: mg/g Cr): Group A; UAI<30, Group B; 30<UAI<300, Group C; UAI>300. The effect of albuminuria on plasma TAT levels was significant (p<0.02). Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks significantly (p<0.0005) decreased plasma TAT levels. These data indicate that the degree of diabetic albuminuria is related to plasma TAT levels in NIDDM patients and that treatment with EPA may reduce TAT levels and possibly therefore the rate of development of CVD in patients with NIDDM.